Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The role of adjuvants in the efficacy of a peptide vaccine for myasthenia gravis
Autore:
McAnally, JL; Xu, LK; Villain, M; Blalock, JE;
Indirizzi:
Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA Univ Alabama Birmingham AL USA 35294 & Biophys, Birmingham, AL 35294 USA Univ Alabama, Ctr Neuroimmunol, Birmingham, AL 35294 USA Univ Alabama Birmingham AL USA 35294 uroimmunol, Birmingham, AL 35294 USA
Titolo Testata:
EXPERIMENTAL BIOLOGY AND MEDICINE
fascicolo: 4, volume: 226, anno: 2001,
pagine: 307 - 311
SICI:
1535-3702(200104)226:4<307:TROAIT>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
EXPERIMENTAL AUTOIMMUNE MYASTHENIA; MYELIN BASIC-PROTEIN; MONOCLONAL ANTIIDIOTYPIC ANTIBODIES; ANTI-IDIOTYPIC ANTIBODIES; ACETYLCHOLINE-RECEPTOR; COMPLEMENTARY PEPTIDE; MESSENGER-RNA; LEWIS RATS; T-CELLS; BINDING;
Keywords:
adjuvant; complementary peptide vaccine; myasthenia gravis; autoimmunity;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
39
Recensione:
Indirizzi per estratti:
Indirizzo: Blalock, JE Univ Alabama, Dept Physiol & Biophys, 1918 Univ Blvd,MCLM 896,Birmingham,AL 35294 USA Univ Alabama 1918 Univ Blvd,MCLM 896 Birmingham ALUSA 35294 A
Citazione:
J.L. McAnally et al., "The role of adjuvants in the efficacy of a peptide vaccine for myasthenia gravis", EXP BIOL ME, 226(4), 2001, pp. 307-311

Abstract

Myasthenia gravis (MG) and its animal model, experimental autoimmune (EA) MG, are caused by interference with neuromuscular transmission by autoantibodies against the nicotinic acetylcholine receptor (AChR) on muscle. Previously, we have shown that two peptides, denoted RhCA 67-16 and RhCA 611-001,designed to be complementary in structure to the main immunogenic region and the dominant Lewis rat T cell epitope (cu-chain residues 100-116) of theAChR, respectively, are effective vaccines that prevent EAMG in rats by inducing anti-idiotypic/clonotypic antibodies (Ab) and lowering levels of AChR Ab. These studies employed keyhole limpet hemocyanin (KLH) as a carrier and complete Freunds adjuvant (CFA). In advance of a clinical trial the present study tested the efficacy of RhCA 611-001 when combined with different adjuvants that are approved for use in humans. Adjuvants chosen for comparison were incomplete freunds adjuvant (IFA) and aluminum hydroxide (Alum), As a second goat we evaluated diphtheria toxin (DT) as an alternative carrier protein to KLH. Alum was found to be an effective adjuvant, particularly when used with the peptide conjugated to UT. This combination of carrier and adjuvant provided protection against EAMG comparable with that observed with CFA and KLH, Using enzyme-linked immunosorbent assays for Ab against RhCA 611-001, it was found that disease protection is qualitatively, but not quantitatively, related to the anti-peptide Ab response. Our results demonstrate a vaccine formulation that should be useful in the first soon-to-be-conducted clinical trials of peptide vaccines to specifically correct aberrant T and B cell responses in an autoimmune disease.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/08/20 alle ore 06:10:08